Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Celecoxib is a nonsteroidal anti-inflammatory drug
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated